bit.ly/3pAK6Oe
Important considerations/caveats:
✨Choice between baricitinib & IL-6RB for severe/critical COVID-19 depends on availability & clinical/contextual factors.
✨In non-severe illness, molnupiravir, sotrivimab & casirivimab-imdevimab are weakly recommended for those at highest risk.
Dec 7, 2021 • 9 tweets • 13 min read
🔊Our latest @WHO living guidance on treatments for #COVID19, out today:
For severe/critical:
✅steroids
✅IL-6 RB
🟨mAb
🟧convalescent plasma🔥
For non-severe:
🟨mAb
🟧steroids
🚫convalescent plasma🔥
For both:
🟧remdesivir
🟧ivermectin
🚫HCQ
🚫LPV/r
bit.ly/3pAK6Oe
Two recommendations:
🌟against administering convalescent plasma for non-severe covid-19.
🌟against administering convalescent plasma for severe or critical covid-19, except in the context of a clinical trial.